Exposure to endocrine disrupting chemicals (EDCs) and cardiometabolic indices during pregnancy: The HOME Study. (November 2021)

• Record Type: Journal Article
• Authors: Vuong, Ann M.; Braun, Joseph M.; Sjödin, Andreas; Calafat, Antonia M.; Yolton, Kimberly; Lanphear, Bruce P.; Chen, Aimin
• Is Part Of: Environment international. Volume 156(2021)
• Publication Date: 2021-11
• Subjects: Bisphenol A (BPA) -- Polybrominated diphenyl ethers (PBDEs) -- Per- and polyfluoroalkyl substances (PFAS) -- Phthalates -- Glucose -- Lipids; Environmental protection -- Periodicals; Environmental health -- Periodicals; Environmental monitoring -- Periodicals; Environmental Monitoring -- Periodicals; Environnement -- Protection -- Périodiques; Hygiène du milieu -- Périodiques; Environnement -- Surveillance -- Périodiques; Environmental health; Environmental monitoring; Environmental protection; Periodicals; 333.705
• DOI: 10.1016/j.envint.2021.106747
• Languages: English
• ISSNs: 0160-4120

Abstract

Highlights: BDE-28 was positively associated with glucose during pregnancy in single- and multi-pollutant models. Increases in BDE-28, BDE-47, and BDE-99 were associated with higher cholesterol. Inverse associations were noted between BDE-153, MBP, and MBzP with cholesterol. We did not find a consistent relationship with any EDC and blood pressure between the models. No relationship was noted between BPA or PFAS with cardiometabolic indices during pregnancy between the models. Abstract: Background: Toxicology studies have identified pregnancy as a window of susceptibility for endocrine disrupting chemicals (EDCs) and cardiometabolic indices in women. No study in humans, however, has examined EDC mixtures and cardiometabolic indices during pregnancy. Methods : We used the Health Outcomes and Measures of the Environment (HOME) Study to examine whether bisphenol A (BPA), polybrominated diphenyl ethers (PBDEs), per- and polyfluoroalkyl substances (PFAS), and phthalates are associated with blood pressure, glucose, and lipids in 388 pregnant women. We measured PBDEs and PFAS in serum at 16 weeks gestation, while BPA and phthalate metabolites were quantified in urine at 16 and 26 weeks gestation. We used linear regression and Bayesian Kernel Machine Regression (BKMR) to estimate covariate-adjusted associations of individual EDCs and their mixtures with cardiometabolic indices during pregnancy. Results : A 10-fold increase in BDE-28 was associated with a 13.1 mg/dL increase in glucose (95% Confidence Interval [CI] 2.9, 23.2) in linear regression. The BKMR model also identified BDE-28 as having a positive association with glucose. BDE-28, BDE-47, and BDE-99 were positively associated with total cholesterol in both single- and multi-pollutant models, whereas a suggestive negative association was noted with BDE-153. Mono-n-butyl phthalate (MBP) (β = -7.9 mg/dL, 95% CI −12.9, −3.0) and monobenzyl phthalate (MBzP) (β = −6.3 mg/dL, 95% CI −10.6, −2.0) were both associated with significant decreases in cholesterol in linear regression, but only MBzP was identified as an important contributor in the BKMR model. Conclusion : Overall, we observed positive associations between PBDEs with glucose and cholesterol levels during pregnancy, while negative associations were found between some phthalate biomarkers and cholesterol. No relationship was noted for BPA or PFAS with cardiometabolic indices during pregnancy across both models.